The global cardiovascular drugs market size accounted for USD 155.96 billion in 2025 and is forecasted to hit around USD 214.72 billion by 2034, representing a CAGR of 3.62% from 2025 to 2034. The North America market size was estimated at USD 38.45 billion in 2024 and is expanding at a CAGR of 2.91% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. End Users Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cardiovascular Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cardiovascular Drugs Market, by Drug Type
8.1.1. Antihypertensive
8.1.1.1. Market Revenue and Forecast
8.1.2. Anticoagulants
8.1.2.1. Market Revenue and Forecast
8.1.3. Antihyperlipidemic
8.1.3.1. Market Revenue and Forecast
8.1.4. Antiplatelet Drugs
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Cardiovascular Drugs Market, by Disease Indication
9.1.1. Hypertension
9.1.1.1. Market Revenue and Forecast
9.1.2. Coronary Artery Disease
9.1.2.1. Market Revenue and Forecast
9.1.3. Hyperlipidaemia
9.1.3.1. Market Revenue and Forecast
9.1.4. Arrhythmia
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Cardiovascular Drugs Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Cardiovascular Drugs Market, by Drug Classification
11.1.1. Branded Drugs
11.1.1.1. Market Revenue and Forecast
11.1.2. Generic Drugs
11.1.2.1. Market Revenue and Forecast
12.1. Cardiovascular Drugs Market, by Mode of Purchase
12.1.1. Prescription-Based Drugs
12.1.1.1. Market Revenue and Forecast
12.1.2. Over-The-Counter Drugs
12.1.2.1. Market Revenue and Forecast
13.1. Cardiovascular Drugs Market, by End Users
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast
13.1.2. Online Pharmacies
13.1.2.1. Market Revenue and Forecast
13.1.3. Retail Pharmacies
13.1.3.1. Market Revenue and Forecast
13.1.4. Others
13.1.4.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Type
14.1.2. Market Revenue and Forecast, by Disease Indication
14.1.3. Market Revenue and Forecast, by Route of Administration
14.1.4. Market Revenue and Forecast, by Drug Classification
14.1.5. Market Revenue and Forecast, by Mode of Purchase
14.1.6. Market Revenue and Forecast, by End Users
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Drug Type
14.1.7.2. Market Revenue and Forecast, by Disease Indication
14.1.7.3. Market Revenue and Forecast, by Route of Administration
14.1.7.4. Market Revenue and Forecast, by Drug Classification
14.1.8. Market Revenue and Forecast, by Mode of Purchase
14.1.8.1. Market Revenue and Forecast, by End Users
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Type
14.1.9.2. Market Revenue and Forecast, by Disease Indication
14.1.9.3. Market Revenue and Forecast, by Route of Administration
14.1.9.4. Market Revenue and Forecast, by Drug Classification
14.1.10. Market Revenue and Forecast, by Mode of Purchase
14.1.11. Market Revenue and Forecast, by End Users
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Type
14.2.2. Market Revenue and Forecast, by Disease Indication
14.2.3. Market Revenue and Forecast, by Route of Administration
14.2.4. Market Revenue and Forecast, by Drug Classification
14.2.5. Market Revenue and Forecast, by Mode of Purchase
14.2.6. Market Revenue and Forecast, by End Users
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Type
14.2.8.2. Market Revenue and Forecast, by Disease Indication
14.2.8.3. Market Revenue and Forecast, by Route of Administration
14.2.9. Market Revenue and Forecast, by Drug Classification
14.2.10. Market Revenue and Forecast, by Mode of Purchase
14.2.10.1. Market Revenue and Forecast, by End Users
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Drug Type
14.2.11.2. Market Revenue and Forecast, by Disease Indication
14.2.11.3. Market Revenue and Forecast, by Route of Administration
14.2.12. Market Revenue and Forecast, by Drug Classification
14.2.13. Market Revenue and Forecast, by Mode of Purchase
14.2.14. Market Revenue and Forecast, by End Users
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Drug Type
14.2.15.2. Market Revenue and Forecast, by Disease Indication
14.2.15.3. Market Revenue and Forecast, by Route of Administration
14.2.15.4. Market Revenue and Forecast, by Drug Classification
14.2.16. Market Revenue and Forecast, by Mode of Purchase
14.2.16.1. Market Revenue and Forecast, by End Users
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Drug Type
14.2.17.2. Market Revenue and Forecast, by Disease Indication
14.2.17.3. Market Revenue and Forecast, by Route of Administration
14.2.17.4. Market Revenue and Forecast, by Drug Classification
14.2.18. Market Revenue and Forecast, by Mode of Purchase
14.2.18.1. Market Revenue and Forecast, by End Users
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Type
14.3.2. Market Revenue and Forecast, by Disease Indication
14.3.3. Market Revenue and Forecast, by Route of Administration
14.3.4. Market Revenue and Forecast, by Drug Classification
14.3.5. Market Revenue and Forecast, by Mode of Purchase
14.3.6. Market Revenue and Forecast, by End Users
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Drug Type
14.3.7.2. Market Revenue and Forecast, by Disease Indication
14.3.7.3. Market Revenue and Forecast, by Route of Administration
14.3.7.4. Market Revenue and Forecast, by Drug Classification
14.3.8. Market Revenue and Forecast, by Mode of Purchase
14.3.9. Market Revenue and Forecast, by End Users
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Drug Type
14.3.10.2. Market Revenue and Forecast, by Disease Indication
14.3.10.3. Market Revenue and Forecast, by Route of Administration
14.3.10.4. Market Revenue and Forecast, by Drug Classification
14.3.11. Market Revenue and Forecast, by Mode of Purchase
14.3.11.1. Market Revenue and Forecast, by End Users
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Drug Type
14.3.12.2. Market Revenue and Forecast, by Disease Indication
14.3.12.3. Market Revenue and Forecast, by Route of Administration
14.3.12.4. Market Revenue and Forecast, by Drug Classification
14.3.12.5. Market Revenue and Forecast, by Mode of Purchase
14.3.12.6. Market Revenue and Forecast, by End Users
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Drug Type
14.3.13.2. Market Revenue and Forecast, by Disease Indication
14.3.13.3. Market Revenue and Forecast, by Route of Administration
14.3.13.4. Market Revenue and Forecast, by Drug Classification
14.3.13.5. Market Revenue and Forecast, by Mode of Purchase
14.3.13.6. Market Revenue and Forecast, by End Users
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Type
14.4.2. Market Revenue and Forecast, by Disease Indication
14.4.3. Market Revenue and Forecast, by Route of Administration
14.4.4. Market Revenue and Forecast, by Drug Classification
14.4.5. Market Revenue and Forecast, by Mode of Purchase
14.4.6. Market Revenue and Forecast, by End Users
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Drug Type
14.4.7.2. Market Revenue and Forecast, by Disease Indication
14.4.7.3. Market Revenue and Forecast, by Route of Administration
14.4.7.4. Market Revenue and Forecast, by Drug Classification
14.4.8. Market Revenue and Forecast, by Mode of Purchase
14.4.9. Market Revenue and Forecast, by End Users
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Drug Type
14.4.10.2. Market Revenue and Forecast, by Disease Indication
14.4.10.3. Market Revenue and Forecast, by Route of Administration
14.4.10.4. Market Revenue and Forecast, by Drug Classification
14.4.11. Market Revenue and Forecast, by Mode of Purchase
14.4.12. Market Revenue and Forecast, by End Users
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Drug Type
14.4.13.2. Market Revenue and Forecast, by Disease Indication
14.4.13.3. Market Revenue and Forecast, by Route of Administration
14.4.13.4. Market Revenue and Forecast, by Drug Classification
14.4.13.5. Market Revenue and Forecast, by Mode of Purchase
14.4.13.6. Market Revenue and Forecast, by End Users
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Drug Type
14.4.14.2. Market Revenue and Forecast, by Disease Indication
14.4.14.3. Market Revenue and Forecast, by Route of Administration
14.4.14.4. Market Revenue and Forecast, by Drug Classification
14.4.14.5. Market Revenue and Forecast, by Mode of Purchase
14.4.14.6. Market Revenue and Forecast, by End Users
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Type
14.5.2. Market Revenue and Forecast, by Disease Indication
14.5.3. Market Revenue and Forecast, by Route of Administration
14.5.4. Market Revenue and Forecast, by Drug Classification
14.5.5. Market Revenue and Forecast, by Mode of Purchase
14.5.6. Market Revenue and Forecast, by End Users
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Drug Type
14.5.7.2. Market Revenue and Forecast, by Disease Indication
14.5.7.3. Market Revenue and Forecast, by Route of Administration
14.5.7.4. Market Revenue and Forecast, by Drug Classification
14.5.8. Market Revenue and Forecast, by Mode of Purchase
14.5.8.1. Market Revenue and Forecast, by End Users
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Type
14.5.9.2. Market Revenue and Forecast, by Disease Indication
14.5.9.3. Market Revenue and Forecast, by Route of Administration
14.5.9.4. Market Revenue and Forecast, by Drug Classification
14.5.9.5. Market Revenue and Forecast, by Mode of Purchase
14.5.9.6. Market Revenue and Forecast, by End Users
15.1. Bristol-Myers Squibb Company
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiative
15.2. Bayer AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Janssen Pharmaceuticals, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Novartis AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Merck & Co.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. AstraZeneca
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Gilead Sciences, Inc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. F. Hoffmann-La Roche
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample